WOMENS ISCHEMIC SYNDROME EVALUATION

UAB是参与妇女缺血综合征评估（WISE）的四个临床站点之一，由NHLBI赞助。WISE是一项为期3年的研究，旨在开发更好的工具来检测女性心肌缺血。潜在的前提是，目前所有可用的临床试验在检测女性心肌缺血方面的可靠性都低于男性。在UAB，我们计划通过钆磁共振成像和混合铊/赛斯米比显像同时评估静止/持久心肌灌注检测缺血的敏感性和特异性。其他机构将测试不同的方式，包括MRI冠状动脉造影、多巴酚丁胺MRI标记、多巴酚丁胺超声心动图、PET和心肌造影超声心动图。UAB的一个由234名妇女组成的研究小组（30%为少数民族）将与其他参与WISE的中心收集某些共同数据，包括详细的社会心理/症状问卷、女性激素评估、动态心电图和冠状动脉造影。诊断测试完成后，将在研究期间每隔6个月进行一次电话联系，以评估患者的生命状况和发病率。

UAB is one of four clinical sites participating in the Women's Ischemic Syndrome Evaluation (WISE), sponsored by the NHLBI. WISE is a 3 year study which seeks to develop better tools for detecting myocardial ischemia in women. The underlying premise is that all currently available clinical tests have a lower reliability for detecting myocardial ischemia in women than in men. At UAB, we plan to evaluate the sensitivity and specificity of detecting ischemia with rest/persantine myocardial perfusion as assessed simultaneously by gadolinium-MRI and by hybrid thallium/sestamibi scintigraphy. Other institutions will be testing different modalities including MRI coronary arteriography, dobutamine MRI tagging, dobutamine echocardiography, PET, and myocardial contrast echocardiography. A study group of 234 women at UAB, 30% minority, will have certain common data collected with the other participating WISE centers, including a detailed psychosocial/symptoms questionnaire, female hormone assessment, ambulatory ECG and coronary arteriography. Following completion of diagnostic testing, telephone contact will be made at 6 month intervals for the duration of the study to assess vital status and morbidity.